Indivior facing lawsuit from 35 states and DC

Indivior updated the market on the Federal Trade Commission investigation and class action litigation being filed against it on Friday.

On 29 July, the FTSE 250 company indicated that the FTC was seeking court action over the drug Suboxone, having investigated whether Indivior and its predecessor, Reckitt Benckiser US, had filed a citizen petition with the Food and Drug Administration and negotiated with competing manufacturers to maintain its monopoly.

It now faced a much larger opponent, with 35 US states and the District of Columbia filing a civil complaint alleging violations of state and federal antitrust and consumer protection laws on Thursday.

“The company intends to continue to vigorously defend its position,” Indivior’s board confirmed.